Amarin sells drug development subsidiary to Watson Pharmaceuticals

Published: 30-Oct-2003

UK-based Amarin Corporation is selling Gacell Holdings, the Swedish holding company of Amarin Development AB (ADAB), its Swedish drug development subsidiary, to Watson Pharmaceuticals for US$15m (€12.83m) in cash.


UK-based Amarin Corporation is selling Gacell Holdings, the Swedish holding company of Amarin Development AB (ADAB), its Swedish drug development subsidiary, to Watson Pharmaceuticals for US$15m (€12.83m) in cash.

ADAB develops technically challenging products utilising advanced, proprietary product development technologies and was responsible for developing Watson's generic formulations of glipizide extended release tablets, approved by the FDA in September.

'The sale of Amarin Development allows us to increase our focus in the field of neurology, specifically in Parkinson's and Huntington's disease,' said Amarin ceo Rick Stewart. Amarin will apply 90% of the net sale proceeds of ADAB toward repayment of its financial obligations to Elan Corporation and certain of its affiliates.

Amarin recently announced a restructuring of its financial obligations to Elan. On payment of $30m to Elan prior to 31 December, 2003, Amarin will have no further financial obligations to Elan.

  

You may also like